



insideReg

Dedicated to your regulatory success

Proof of Concept to Phase I



CONTENTS

Where do we start?

Welcome to Phase I

R&D and
Regulatory Roadmaps

Small & Medium
Enterprise status

Chemistry, Manufacturing
and Controls

Non-Clinical Studies

Clinical Strategy

Preparing for submission
of Clinical Trial Application

Proof of Concept to Phase I

Where do we start?

For small and medium-sized companies with great ideas, developing a new medicine can seem overwhelming. High cost, high risk and high expectations. Sound familiar? With the right support, innovative medicines represent unparalleled opportunities to make a real difference, even at Clinical Trial stage.

With the right support, innovative medicines represent unparalleled opportunities to make a real difference

InsideReg is a Regulatory Affairs Consultancy founded in 2018 by ex MHRA Quality Assessor Dr Laura Millichamp. The Company mission is to use unique insights and expertise to advance the development and registration of human medicinal products indicated in the prevention and treatment of diseases.

All our Subject Matter Experts bring tens of years' experience to the team, and most are ex-regulatory authority assessors.

This uniquely positions them to share key insights into the workings of the Regulatory Authorities, their mindsets and likely approaches on Clinical, Non-Clinical and CMC issues.

We know that your product is unique, and so we focus on creating teams bespoke approach to each project, optimising alignment between SME and client. There are no layers of management, and each SME works directly with the client counterpart.

This personal approach means that we blend seamlessly into your team, working alongside each of you to support your company objectives.

In this brochure, we summarise the key steps that you will make on your initial journey to a First in Human Clinical trial, outlining the support you will need, together with ballpark cost estimates to help you plan.



Welcome to Phase I

Following establishment of a start-up, the journey begins with winning funding from investors, building relationships with partners, advisors and the team that will support you on your journey.

None of us achieve success alone, and trusted teams are key. Not just for obtaining funding, where investors need to feel that rapport with, and to believe in, the leadership team, but in making the right strategic decisions.

R&D and Regulatory Strategy roadmaps are critical to this.

A clear regulatory strategy is the vital foundation to the financial planning of a company and a key feature in presentations to investors and potential partners. That isn't enough. It is not enough to have secure funding and a great team. We also need regulatory support and approvals.

Communicating a clear vision and strategy is critical to securing funding and support for the development of a new medicinal product.



R&D and Regulatory Roadmaps

Prefer to stick to what you know? We do too, so whilst you develop the science, we position the product and develop the strategy. At InsideReg, we create R&D and Regulatory roadmaps, setting out clear milestones and data to be generated at each stage of development.

We support you with:

Regulatory landscape analysis:

The roadmap starts with a regulatory landscape analysis, reviewing the currently approved medicinal products and clinical trials for similar compounds in the same or similar indications. This identifies regulatory precedence and the likely regulatory expectations from the outset.

A de-risking approach:

It is never too early to seek scientific advice from the Regulatory Authorities.

Streamline data generation:

With our teams comprised of or including ex-Agency Assessors, we deliver development plans that focus on generating only the data that is needed, thus moving efficiently through the studies to that all important First Patient In date.

Focus on value generation:

A R&D and regulatory roadmap sets out the studies needed, along with the timelines and costings, and key milestones. Not only does this structure the plan and progress but demonstrates that the leadership team have a clear vision of the steps to success.

SME status

Need to reduce costs? A Micro, Small and Medium sized Enterprise is defined by the European Commission as having fewer than 250 employees and an annual turnover of not more than €50 million, or an annual balance sheet of not more than €43 million. For most companies at early stages of development, these criteria are easily met. The benefits of being a registered SME include:

- ✓ SME briefing meeting for early engagement with a multidisciplinary EMA team
- ✓ Support and guidance for questions regarding regulatory procedures and strategy
- ✓ Guidance on clinical data publication
- ✓ Translations of product information into all official EU languages at MAA stage
- ✓ For companies developing paediatric medicines, support finding academic partners through the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)).
- ✓ Financial incentives: 90% fee reduction for Scientific Advice, inspections and scientific services


We support you with:

SME holding:

Many start-ups are based outside the European Union and are therefore unable to access this support, and with the cost of maintaining a legal entity in the EU starting at approximately 3500 Euros per annum. By using InsideReg's SME status through our office in Ireland, we hold the SME status on your behalf until you are ready to establish a legal entity in the EU.

Application Process:

We guide you through the entire application process, managing all communications with EMA on your behalf, ensuring a smooth and timely approval.



Chemistry, Manufacturing & Controls

Ready to progress from the lab to a manufacturing suite? Great! Now is the time to extend the collaboration to a CDMO and get the first batch under way.

The medicinal product to be administered in a Phase I clinical trial, needs to be safe and manufactured in accordance with GMP. The manufacturing process is often still under development at this stage and the data can be variable. Regulatory Authorities expect that the product is safe but with minimal small scale batch data available, activities such as setting specifications can be challenging.

All our CMC Experts are ex-Regulatory Authority Assessors, each with over 15 years' experience in the regulatory and technical aspects of CMC. We can focus on a defined project such as developing a comparability plan/protocol, writing scientific advice/agency meeting briefing books, but also regularly accompany clients throughout their development journey, holding positions such as "Acting Director of CMC", or just by remaining available to support calls, meetings and ad hoc questions.

We support you with:

Streamlining data generation: Identifying the necessary data to be generated that is sufficient for the assessor to make their decision, but not so much that it becomes expensive.

De-risking approach: our CMC experts have many years of experience in data submission and requirements at early stages of development, enabling them to advise on challenges such as specification setting and minimum data requirements for approval.

CDMO relationship management: The reports generated by CDMOs are the source data for the regulatory documents. An early review by a regulatory expert ensures that no data is missed and that clear audit trail from IMPD to source data is maintained.

Ad hoc advice:

At this stage of development, minor questions arise frequently.

*Our Experts are on hand to advise quickly and clearly,
facilitating decision making and progress
towards that first clinical trial batch.*



Non-Clinical Studies

Non-Clinical studies can be time consuming and expensive. Animal model selection, number of animals to be used, and duration of studies, are some of the key questions on which we advise. Whilst most projects we support generate their own data package, some are known active substances for which we can cross-refer at least in part to literature or other data. Knowing the available options at the outset means that we can develop a clear non-clinical data generation pathway, streamlined and optimised. Ad hoc advice from a Non-Clinical Expert can be invaluable in answering these questions during this stage, particularly when they have a background as an Assessor/reviewer.

Knowing the available options at the outset means that we can develop a clear non-clinical data generation pathway

Once data is generated, writing up reports or reviewing those generated by CRO are critical to ensuring a smooth Phase I clinical trial application that is well written and demonstrates an acceptable safety profile.

We support you with:

Streamlining data generation:
Identifying the necessary data to be generated that is sufficient for the assessor to make their decision, but not so much that it becomes un-necessarily expensive.

De-risking approach:

Our Non-Clinical experts have many years of experience in data submission and requirements at early stages of development, enabling them to advise on critical decisions such as animal model selection, number of animals, study design and duration.

CRO relationship management:

The reports generated by CROs are the source data for the regulatory documents. An early review by a Non-Clinical expert can identify early on any data that might need more careful positioning during presentation to regulatory authorities.

Ad hoc advice:

At this stage of development, minor questions arise frequently. Our Experts are on hand to advise quickly and clearly, facilitating decision making and progress towards that first clinical trial approval.

By engaging a Non-Clinical Expert throughout the development stages, challenges are quickly addressed in the manner expected by regulators and the program kept moving in the direction of success.

Troubleshooting:

This is research, and we understand that despite best efforts, sometimes not everything goes according to Plan A. By engaging a Non-Clinical Expert throughout the development stages, challenges are quickly addressed in the manner expected by regulators and the program kept moving in the direction of success.

Clinical Strategy

Development of novel therapies requires a combination of extensive clinical development, regulatory expertise and operational excellence to ensure success and overcome potential hurdles in a right-first time manner. At InsideReg, this is achieved by ensuring optimum alignment of Consultant expertise and client needs to deliver high quality advice and continuous support in your development journey.

Our Clinical Experts have tens of years' experience in designing Clinical Study Protocols that are acceptable to Regulatory Authorities

We support you with:

Indication definition and selection:

A Gap Analysis of the background development work completed thus far and scientific rationale for next proposed development strategy will underpin product positioning, defining the indication(s) most likely to be of interest from both a medical and a commercial perspective.

Clinical Strategy:

The key conceptual design elements of a clinical study protocol are outlined, with focus on key areas such justification of endpoints, clinically relevant effect sizes, study size, recruitment ease, number of centres. Opportunities for protocol and programme acceleration are identified and are presented together with topline costings and timings.

Clinical Development Plan:

The CDP is a living document and is expected to change based on emerging data, operational constraints and changes in the overall approach. The CDP is an expansion of the Clinical Strategy, providing a more granular and detailed approach to the programme, expertly positioned to be credible, and optimised for regulatory acceptance.

Clinical Study Protocol Authoring:

Our Clinical Experts have tens of years' experience in designing Clinical Study Protocols that are acceptable to Regulatory Authorities. A natural follow on activity from the Clinical Strategy and CDP development, we can support you as much or as little as you need from a high level review with a regulatory focus, to full authoring starting from the CDP.

Preparing for submission of Phase I Clinical Trial Application

A Phase I Clinical Trial Application is likely to be the first submission, so making the right impression is vital to initiating a good relationship with the Regulatory Authorities. If we haven't met prior to this stage, or perhaps you have acquired an asset from another company, a high level gap analysis can be useful to identify any data gaps, and develop the right strategies prior to submission. The dossier should be well written, using the correct language and phrasing, to facilitate the assessor's review. Any challenging data should be carefully positioned and a risk mitigation plan put in place to manage questions so that approval timelines can be kept.

*Making the right impression is vital to initiating
a good relationship with the Regulatory Authorities*

Whilst the EU now uses a centralised submission platform (CTIS) for simultaneous submission & approval of CTAs, the UK & Switzerland are outside the EU and have their own submission pathways. We provide local representation in both markets.

We support you with:

Data requirements checklist:

Our highly experienced regulatory experts have developed checklists to streamline the gap analysis and ensure that everything is present and correct for that right first time submission.

Submissions:

We collate and check all the documents, to ensure a complete submission is made from the outset, taking applications smoothly through validation and into the review phase.

Communication with regulatory authorities:

We take the lead and manage all the communications with the Regulatory Authorities on your behalf, so that you can focus on ongoing activities. Any questions received are reviewed by our Experts so that we can support you in positioning responses and submitting them in a timely manner, minimising the time to approval.

